Exposing Drug Industry Funding of UK Patient Organisations

Overview

Journal BMJ

Specialty General Medicine

Date 2019 May 25

PMID 31122928

Citations 23

Authors

Piotr Ozieranski

Emily Rickard

Shai Mulinari

Affiliations

Soon will be listed here.

Citing Articles

How are patient inputs considered in HTA? A thematic document analysis of NICE ultra-rare disease appraisals.

Gentilini A, Rana A Eur J Health Econ. 2024; .

PMID: 39725821 DOI: 10.1007/s10198-024-01748-1.

Commercial influences on patient and public involvement: a renewed call for research and action.

Hennessy M, Fahey T, Larkin J Health Promot Int. 2024; 39(6).

PMID: 39657731 PMC: 11631069. DOI: 10.1093/heapro/daae188.

Pharmaceutical industry payments to healthcare professional organisations in the United Kingdom: a seven-year cross-sectional analysis of the Disclosure UK database from 2015 to 2021.

Murayama A, Fabbri A, Scholfield H, Ozieranski P J R Soc Med. 2024; 118(1):16-25.

PMID: 39556206 PMC: 11574929. DOI: 10.1177/01410768241297441.

Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database.

Ozieranski P, Saghy E, Mulinari S PLoS One. 2023; 18(11):e0290022.

PMID: 37910526 PMC: 10619808. DOI: 10.1371/journal.pone.0290022.

Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence.

Gentilini A, Parvanova I BMJ Open. 2023; 13(6):e071138.

PMID: 37369404 PMC: 10410975. DOI: 10.1136/bmjopen-2022-071138.

References

Ferner R, McDowell S . How NICE may be outflanked. BMJ. 2006; 332(7552):1268-71. PMC: 1471969. DOI: 10.1136/bmj.332.7552.1268. View

Kent A . Should patient groups accept money from drug companies? Yes. BMJ. 2007; 334(7600):934. PMC: 1865450. DOI: 10.1136/bmj.39185.461968.AD. View

Mintzes B . Should patient groups accept money from drug companies? No. BMJ. 2007; 334(7600):935. PMC: 1865416. DOI: 10.1136/bmj.39185.394005.AD. View

Baggott R, Forster R . Health consumer and patients' organizations in Europe: towards a comparative analysis. Health Expect. 2008; 11(1):85-94. PMC: 5060431. DOI: 10.1111/j.1369-7625.2007.00472.x. View

Jones K . In whose interest? Relationships between health consumer groups and the pharmaceutical industry in the UK. Sociol Health Illn. 2008; 30(6):929-43. DOI: 10.1111/j.1467-9566.2008.01109.x. View

Mold A . Patient Groups and the Construction of the Patient-Consumer in Britain: An Historical Overview. J Soc Policy. 2010; 39(4):505-521. PMC: 2925204. DOI: 10.1017/S0047279410000231. View

Rothman S, Raveis V, Friedman A, Rothman D . Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices. Am J Public Health. 2011; 101(4):602-9. PMC: 3052325. DOI: 10.2105/AJPH.2010.300027. View

Colombo C, Mosconi P, Villani W, Garattini S . Patient organizations' funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey. PLoS One. 2012; 7(5):e34974. PMC: 3348919. DOI: 10.1371/journal.pone.0034974. View

Mulinari S . Regulating drug information in Europe: a pyrrhic victory for pharmaceutical industry critics?. Sociol Health Illn. 2012; 35(5):761-77. DOI: 10.1111/j.1467-9566.2012.01528.x. View

10.

Hughes D, Williams-Jones B . Coalition Priorité Cancer and the pharmaceutical industry in Quebec: conflicts of interest in the reimbursement of expensive cancer drugs?. Healthc Policy. 2013; 9(1):52-64. PMC: 3999544. View

11.

Sismondo S . Key opinion leaders and the corruption of medical knowledge: what the Sunshine Act will and won't cast light on. J Law Med Ethics. 2013; 41(3):635-43. DOI: 10.1111/jlme.12073. View

12.

Baggott R, Jones K . The Big Society in an age of austerity: threats and opportunities for Health Consumer and Patients' Organizations in England. Health Expect. 2014; 18(6):2164-73. PMC: 5810728. DOI: 10.1111/hex.12185. View

13.

Fisher J, Cottingham M, Kalbaugh C . Peering into the pharmaceutical "pipeline": investigational drugs, clinical trials, and industry priorities. Soc Sci Med. 2014; 131:322-30. PMC: 4334744. DOI: 10.1016/j.socscimed.2014.08.023. View

14.

Gellad W, Flynn K, Alexander G . Evaluation of Flibanserin: Science and Advocacy at the FDA. JAMA. 2015; 314(9):869-70. DOI: 10.1001/jama.2015.8405. View

15.

Vilhelmsson A, Davis C, Mulinari S . Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012. PLoS Med. 2016; 13(1):e1001945. PMC: 4727894. DOI: 10.1371/journal.pmed.1001945. View

16.

DeJong C, Aguilar T, Tseng C, Lin G, Boscardin W, Dudley R . Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. JAMA Intern Med. 2016; 176(8):1114-1122. DOI: 10.1001/jamainternmed.2016.2765. View

17.

Adlington K, Godlee F . Disclosure UK: transparency should no longer be an optional extra. BMJ. 2016; 354:i3730. DOI: 10.1136/bmj.i3730. View

18.

Kmietowicz Z . Disclosure UK website gives "illusion of transparency," says Goldacre. BMJ. 2016; 354:i3760. DOI: 10.1136/bmj.i3760. View

19.

Fleischman W, Agrawal S, King M, Venkatesh A, Krumholz H, McKee D . Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ. 2016; 354:i4189. PMC: 4989280. DOI: 10.1136/bmj.i4189. View

20.

Abola M, Prasad V . Industry Funding of Cancer Patient Advocacy Organizations. Mayo Clin Proc. 2016; 91(11):1668-1670. DOI: 10.1016/j.mayocp.2016.08.015. View